Ketamine-Enhanced Prolonged Exposure for PTSD

Prolonged exposure (PE) therapy is one of the most well-established treatments for PTSD, with decades of evidence supporting its efficacy. But PE is demanding. It requires patients to repeatedly engage with traumatic memories, a process that causes significant short-term distress and leads to high dropout rates. A 2024 RCT protocol proposes a solution: using ketamine to enhance PE therapy, potentially making the process more tolerable and more effective for veterans with PTSD.

The Challenge with Prolonged Exposure

PE therapy works through a process called extinction learning. Patients repeatedly revisit traumatic memories in a safe therapeutic context until the emotional charge associated with those memories diminishes. Over time, the brain learns that recalling the trauma does not require a full fight-or-flight response. The fear and avoidance that characterize PTSD gradually weaken.

The problem is that extinction learning requires the brain to form new neural connections that compete with and eventually override the original fear-based associations. In PTSD, the neural circuits underlying fear are often deeply entrenched and resistant to change. This is why PE typically requires 8 to 15 sessions of emotionally taxing work, and why 30% to 40% of patients drop out before completing the protocol.

Veterans face particular challenges with PE:

• Combat-related trauma often involves multiple traumatic events, complicating the exposure hierarchy
• High rates of comorbid TBI, depression, and substance use can impair engagement
• Avoidance, a core PTSD symptom, directly opposes the therapeutic requirement to approach traumatic material
• Military culture may reinforce stoicism and resistance to emotional processing

The Ketamine Enhancement Hypothesis

The 2024 RCT protocol is built on a straightforward hypothesis: if ketamine promotes neuroplasticity and enhances the brain's capacity for new learning, administering ketamine before PE sessions could make extinction learning faster, deeper, and more durable.

The rationale draws on several established findings:

Ketamine enhances BDNF and synaptogenesis: The rapid increase in brain-derived neurotrophic factor following ketamine treatment creates a window during which the brain is primed to form new neural connections. Extinction learning is fundamentally about forming new connections that override old ones.

Ketamine modulates fear circuits: Research has shown that ketamine can reduce activity in the amygdala (the brain's fear center) while enhancing prefrontal cortex function. This shift in the balance of neural activity may make it easier for patients to engage with traumatic material without being overwhelmed.

Ketamine reduces avoidance: The acute anxiolytic and antidepressant effects of ketamine may lower the motivational barriers to engaging in exposure work. Patients who feel less depressed and less anxious may be better able to tolerate the discomfort of PE.

Ketamine improves memory reconsolidation: Emerging research suggests that ketamine may facilitate memory reconsolidation, the process by which retrieved memories are updated and re-stored. This could mean that traumatic memories accessed during PE are more amenable to modification when ketamine has been administered.

The Trial Design

The 2024 protocol describes a randomized controlled trial comparing:

• Ketamine + PE: Patients receive a sub-anesthetic ketamine infusion prior to their PE sessions
• Placebo + PE: Patients receive a placebo infusion prior to PE sessions

Both groups receive standard PE therapy delivered by trained therapists. The study measures PTSD symptom severity (using the CAPS-5, the gold-standard clinician-administered PTSD scale), treatment completion rates, and secondary outcomes including depression, quality of life, and functional status.

The trial specifically enrolls veterans with combat-related PTSD, a population with well-documented treatment resistance and high clinical need.

What We Might Expect

While the trial results are not yet available, the combined evidence base provides reason for cautious optimism:

Higher completion rates: If ketamine reduces the emotional burden of exposure work, fewer patients may drop out. Even a modest improvement in completion rates would translate to more veterans receiving the full benefit of PE.

Faster response: Ketamine's neuroplastic effects may accelerate extinction learning, potentially reducing the number of PE sessions needed to achieve symptom reduction. This has practical implications for both patient burden and healthcare system capacity.

Greater symptom reduction: If ketamine enhances the brain's capacity to form competing, non-fear-based associations with traumatic memories, the depth of symptom improvement may exceed what PE alone achieves.

More durable outcomes: Extinction learning mediated by enhanced neuroplasticity may be more resistant to relapse than standard extinction, potentially leading to longer-lasting PTSD remission.

Broader Implications

The ketamine-enhanced PE protocol represents a broader trend in psychiatry: using pharmacological agents to augment established psychotherapies rather than as standalone treatments. This combination approach recognizes that the best outcomes often require addressing both the neurobiological and psychological dimensions of mental health conditions.

For veterans and other PTSD patients, this paradigm shift is particularly promising. PTSD is a condition where the neurobiology (overactive fear circuits, impaired prefrontal function) directly impedes the psychology (the ability to engage in therapeutic exposure). Ketamine may help bridge this gap.

Patients interested in combining ketamine with therapy can explore the Isha Health therapist directory to find providers experienced in ketamine-assisted therapeutic approaches. For more on ketamine research in veteran populations, see our post on ketamine for veterans.

The Bottom Line

Ketamine-enhanced prolonged exposure therapy represents a compelling approach to one of PTSD treatment's most persistent challenges: getting patients through a demanding but effective therapy. The 2024 RCT protocol provides a rigorous framework for testing whether ketamine's neuroplastic and anxiolytic effects can make PE more tolerable, more efficient, and more effective for veterans. The results, when published, could reshape how we approach trauma treatment.

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.